Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Jurnal Kedokteran Methodist
Endy Juli Anto
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Computer Science & IT Decision Sciences, Operations Research & Management Dentistry Earth & Planetary Sciences Education Health Professions Immunology & microbiology Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Neuroscience Nursing Physics Public Health Veterinary Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
A Case of Complete Recovery From Recurrent Bell’s Palsy After Peripheral Blood Stem Cell Transplantation : A Case of Complete Recovery From Recurrent Bell’s Palsy After Peripheral Blood Stem Cell Transplantation lim, hadyanto; Hutasoit, Eka Samuel P; Endy Juli Anto
Jurnal Kedokteran Methodist Vol. 17 No. 1 (2024): Jurnal Kedokteran Methodist
Publisher : Universitas Methodist Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background Recurrent Bell’s palsy is a rare condition that can affect the ipsilateral or contralateral to the affected side of the primary attack. There is still no consensus on treatment guidelines for recurrent Bell’s palsy. Therefore, we report a case of idiopathic recurrent contralateral facial palsy treated with autologous peripheral blood stem cell (PBSC) transplantation. Case Presentation A 72-year-old man presented with the sudden onset of right facial weakness, which was contralateral to the affected side of the first episode of facial palsy. The weakness had progressed with difficulty in closing the right eye, drooling the water from the right side of the mouth, and chewing impairment which was consistent with House Brackmann grade IV or moderately severe facial nerve grading system. He had exposure to cold stimulation, and a history of hypertension. He was given G-CSF 10 ug/kg/day for 5 days to mobilize stem cells, followed by apheresis on the 5th day. He did not receive acupuncture treatment. He had a complete recovery in 3 weeks with House Brackmann grade I or normal function of facial nerve. Conclusion Peripheral blood stem cell transplantation had a beneficial effect on the complete recovery of this recurrent Bell’s palsy and provides a treatment strategy in patients with unilateral facial palsy.
Peran Lutein dan Zeaxanthin dalam Formulasi AREDS 2: Mekanisme Protektif dan Implementasi Klinis pada Age-Related Macular Degeneration: Tinjauan Pustaka Endy Juli Anto; Rusli, Kenvin
Cermin Dunia Kedokteran Vol 53 No 04 (2026): April 2026
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v53i04.2134

Abstract

Lutein and zeaxanthin are carotenoids that serve as key components in the Age-Related Eye Disease Study 2 (AREDS 2) formulation, replacing beta-carotene from the original formulation due to safety concerns. These carotenoids exhibit dual protective mechanisms as blue light filters and antioxidants within the macula. This literature review aims to analyze the specific roles of lutein and zeaxanthin in AREDS 2, their molecular protective mechanisms, and their optimal clinical implementation in age-related macular degeneration (AMD). Literature searches were conducted through PubMed, Cochrane Library, and Google Scholar using the keywords "lutein", "zeaxanthin", "AREDS 2","macular pigment", and "photoprotection". Lutein and zeaxanthin selectively accumulate in the macula, forming macular pigment optical density (MPOD), which functions as blue light filter (400–500 nm) and free radical scavenger. Supplementation with lutein 10 mg and zeaxanthin 2 mg in AREDS 2 has been proven to increase MPOD and reduce the risk of age-related macular degeneration (AMD) progression by 10%–26%. Clinical implementation requires baseline MPOD evaluation, individualized response monitoring, and dose optimization based on nutritional status and patient-specific risk factors.
Co-Authors Hadyanto Lim Hutasoit, Eka Samuel P Rusli, Kenvin